ClinicalTrials.Veeva

Menu
E

Equity Medical, LLC | Bowling Green, KY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Ruxolitinib
EVO756
ESK-001
Ustekinumab
CDX-0159
Litifilimab
Remibrutinib
Rocatinlimab
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 17 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: Matching placebo
Biological: barzolvolimab

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo 1
Drug: Placebo 2

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Enrolling
Atopic Dermatitis
Biological: Barzolvolimab
Drug: Matching placebo

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Lutikizumab

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting
Plaque Psoriasis
Drug: Ustekinumab
Drug: Matching Placebo to Ustekinumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Enrolling
Atoptic Dermatitis
Drug: EVO756
Drug: Placebo control

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...

Enrolling
Cutaneous Squamous Cell Carcinoma (CSCC)
Procedure: Standard of care
Drug: Cemiplimab
Locations recently updated

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Enrolling
Hidradenitis Suppurativa
Drug: Ruxolitinib Cream
Locations recently updated

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling
Hidradenitis Suppurativa (HS)
Biological: Tibulizumab Dose B
Other: Placebo

Trial sponsors

AbbVie logo
Celldex Therapeutics logo
Incyte logo
A
Amgen logo
Biogen logo
E
Janssen (J&J Innovative Medicine) logo
Novartis logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems